Of mice and not humans: How reliable are animal models for evaluation of herpes CD8 +-T cell-epitopes-based immunotherapeutic vaccine candidates?

Vaccine

Volumn 29, Issue 35, 2011, Pages 5824-5836

  Dasgupta, Gargi ^a   BenMohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal model; CD8 + T cells; Genital herpes; HSV 1; HSV 2; Ocular herpes; Therapeutic vaccine

Indexed keywords

EPITOPE; HERPES SIMPLEX VACCINE; HLA ANTIGEN; VIRUS VECTOR;

AOTUS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS INFECTION; EXPERIMENTAL RABBIT; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; MACACA; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SENSORY GANGLION; TRANSGENIC ANIMAL; TRIGEMINUS GANGLION; VACCINIA VIRUS; VIRAL EYE INFECTION; VIRAL SKIN DISEASE; VIRUS ENCEPHALITIS; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HLA ANTIGENS; HUMANS; IMMUNIZATION; KERATITIS, HERPETIC; MICE; RABBITS;

EID: 79960708453     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.083     Document Type: Review

References (182)

1. Morrison L.A. Vaccines against genital herpes: progress and limitations. Drugs 2002, 62(8):1119-1129.
2. Wilson K.M., Triantafilou K., Morrison I.E., Cherry R.J., Fernandez N. Single particle imaging of cell-surface HLA-DR tetramers. Biochem Soc Trans 1997, 25(May (2)):360S.
3. Dasgupta G., Nesburn A.B., Wechsler S.L., BenMohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Fut Microbiol 2010, 5(January (1)):1-4.
4. Dasgupta G., Chentoufi A.A., Nesburn A.B., Wechsler S.L., BenMohamed L. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vacc 2009, 8(August (8)):1023-1035.
5. + T cell response by reducing Th1 cytokines and CCR5 ligand secretion. J Acquir Immune Defic Syndr 2011, PMID: 21646911.
6. Vagvala S.P., Thebeau L.G., Wilson S.R., Morrison L.A. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol 2009, 83(January (2)):953-960.
7. Morrison L.A. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4T cells. Virology 2008, 376(June (1)):205-210.
8. Chentoufi AA, Kritzer E, Tran M, Dasgupta G, Ea R, Xianzhi J, et al. The herpes simplex virus-1 encoded latency-associated transcript promotes dysfunctional virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J Virol; in press.
9. + T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus type 1. J Virol 2011, 85(May (9)):4184-4197.
10. Jiang X., Chentoufi A.A., Hsiang C., Carpenter D., Osorio N., Benmohamed L., et al. The herpes simplex virus type 1 latency associated transcript (LAT) can protect neuronal derived C1300 and Neuro2A cells from Granzyme B induced apoptosis and CD8 T-cell killing. J Virol 2010, (December).
11. Chentoufi A.A., Dasgupta G., Nesburn A.B., Bettahi I., Binder N.R., Choudhury Z.S., et al. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin Vacc Immunol 2010, 17(March (3)):342-353.
12. + T-cell epitope-based vaccines against ocular herpes. J Immunol 2010, 184(Mar (1)):2561-2571.
13. + T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009, 2(March (2)):129-143.
14. Gebhardt B.M., Halford W.P. Evidence that spontaneous reactivation of herpes virus does not occur in mice. Virol J 2005, August (2):67.
15. + T-cell epitope of herpes simplex virus types 1 and 2 increases ocular virus replication and pathogenicity. Invest Ophthalmol Vis Sci 2009, 50(June (6)):2903-2912.
16. Zhang X., Castelli F.A., Zhu X., Wu M., Maillere B., BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vacc Immunol 2008, 15(September (9)):1436-1449.
17. + cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 2008, 180(January (1)):426-437.
18. Taneja V., David C.S. HLA class II transgenic mice as models of human diseases. Immunol Rev 1999, June (169):67-79.
19. Koelle D.M., Reymond S.N., Chen H., Kwok W.W., McClurkan C., Gyaltsong T., et al. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol 2000, 74(December (23)):10930-10938.
20. Tobian A.A., Quinn T.C. Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 2009, 4(July (4)):294-299.
21. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. J Am Med Assoc 1999, 282(July (4)):331-340.
22. Hartley C. Immunologic strategies for herpes vaccination. J Am Med Assoc 2000, 283(February (6)):746. [author reply -7].
23. Friedman H.M. Immunologic strategies for herpes vaccination. J Am Med Assoc 2000, 283(February (6)):746. [author reply -7].
24. Sheridan B.S., Cherpes T.L., Urban J., Kalinski P., Hendricks R.L. Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes. J Virol 2009, 83(March (5)):2237-2245.
25. Liu T., Khanna K.M., Chen X., Fink D.J., Hendricks R.L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191(May (9)):1459-1466.
26. Liu T., Khanna K.M., Carriere B.N., Hendricks R.L. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001, 75(November (22)):11178-11184.
27. + T cells maintain HSV-1 latency. Immunol Res 2006, 36(1-3):119-126.
28. Khanna K.M., Lepisto A.J., Hendricks R.L. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol 2004, 25(May (5)):230-234.
29. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008, 322(October (5899)):268-271.
30. Verjans G.M., Hintzen R.Q., van Dun J.M., Poot A., Milikan J.C., Laman J.D., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci USA 2007, 104(February (9)):3496-3501.
31. Theil D., Arbusow V., Derfuss T., Strupp M., Pfeiffer M., Mascolo A., et al. Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. Brain Pathol 2001, 11(October (4)):408-413.
32. Derfuss T., Segerer S., Herberger S., Sinicina I., Hufner K., Ebelt K., et al. Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol 2007, 17(October (4)):389-398.
33. Bauer D., Wasmuth S., Hennig M., Baehler H., Steuhl K.P., Heiligenhaus A. Amniotic membrane transplantation induces apoptosis in T lymphocytes in murine corneas with experimental herpetic stromal keratitis. Invest Ophthalmol Vis Sci 2009, 50(July (7)):3188-3198.
34. Komatsu K., Miyazaki D., Morohoshi K., Kuo C.H., Kakimaru-Hasegawa A., Komatsu N., et al. Pathogenesis of herpetic stromal keratitis in CCR5- and/or CXCR3-deficient mice. Curr Eye Res 2008, 33(September (9)):736-749.
35. Kaye S., Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res 2006, 25(July (4)):355-380.
36. Banerjee K., Biswas P.S., Rouse B.T. Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. J Leukoc Biol 2005, 77(January (1)):24-32.
37. Stumpf T.H., Case R., Shimeld C., Easty D.L., Hill T.J. Primary herpes simplex virus type 1 infection of the eye triggers similar immune responses in the cornea and the skin of the eyelids. J Gen Virol 2002, 83(July (Pt 7)):1579-1590.
38. Keadle T.L., Morris J.L., Pepose J.S., Stuart P.M. CD4(+) and CD8(+) cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb Pathog 2002, 32(June (6)):255-262.
39. Bauer D., Schmitz A., Van Rooijen N., Steuhl K.P., Heiligenhaus A. Conjunctival macrophage-mediated influence of the local and systemic immune response after corneal herpes simplex virus-1 infection. Immunology 2002, 107(September (1)):118-128.
40. Verjans G.M., Remeijer L., Mooy C.M., Osterhaus A.D. Herpes simplex virus-specific T cells infiltrate the cornea of patients with herpetic stromal keratitis: no evidence for autoreactive T cells. Invest Ophthalmol Vis Sci 2000, 41(August (9)):2607-2612.
41. Chang E., Galle L., Maggs D., Estes D.M., Mitchell W.J. Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice. J Virol 2000, 74(December (24)):11832-11840.
42. Gangappa S., Manickan E., Rouse B.T. Control of herpetic stromal keratitis using CTLA4Ig fusion protein. Clin Immunol Immunopathol 1998, 86(January (1)):88-94.
43. Streilein J.W., Dana M.R., Ksander B.R. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today 1997, 18(September (9)):443-449.
44. Gussow A.M., Giordani N.V., Tran R.K., Imai Y., Kwiatkowski D.L., Rall G.F., et al. Tissue-specific splicing of the herpes simplex virus type 1 latency-associated transcript (LAT) intron in LAT transgenic mice. J Virol 2006, 80(October (19)):9414-9423.
45. Feldman L.T., Ellison A.R., Voytek C.C., Yang L., Krause P., Margolis T.P. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci USA 2002, 99(January (2)):978-983.
46. Ellison A.R., Yang L., Voytek C., Margolis T.P. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. Virology 2000, 268(March (1)):17-28.
47. Margolis T.P., Elfman F.L., Leib D., Pakpour N., Apakupakul K., Imai Y., et al. Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J Virol 2007, 81(October (20)):11069-11074.
48. Yang L., Voytek C.C., Margolis T.P. Immunohistochemical analysis of primary sensory neurons latently infected with herpes simplex virus type 1. J Virol 2000, 74(January (1)):209-217.
49. Openshaw H., Cantin E.M. Corticosteroids in herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005, 76(November (11)):1469.
50. Han X., Lundberg P., Tanamachi B., Openshaw H., Longmate J., Cantin E. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J Virol 2001, 75(March (6)):3048-3052.
51. Lundberg P., Welander P., Openshaw H., Nalbandian C., Edwards C., Moldawer L., et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. J Virol 2003, 77(November (21)):11661-11673.
52. Carr D.J., Harle P., Gebhardt B.M. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med (Maywood) 2001, 226(May (5)):353-366.
53. Polcicova K., Biswas P.S., Banerjee K., Wisner T.W., Rouse B.T., Johnson D.C. Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. Proc Natl Acad Sci USA 2005, 102(August (32)):11462-11467.
54. + cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J Virol 2008, 82(Dec (23)):11792-11802.
55. Kaye S.B., Baker K., Bonshek R., Maseruka H., Grinfeld E., Tullo A., et al. Human herpesviruses in the cornea. Br J Ophthalmol 2000, 84(June (6)):563-571.
56. + T cells accounts for herpetic ocular lesions. Invest Ophthalmol Vis Sci 2000, 41(February (2)):453-459.
57. Gangappa S., Deshpande S.P., Rouse B.T. Bystander activation of CD4(+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur J Immunol 1999, 29(November (11)):3674-3682.
58. Zhao Z.S., Granucci F., Yeh L., Schaffer P.A., Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998, 279(February (5355)):1344-1347.
59. Metcalf J.F., Michaelis B.A. Herpetic keratitis in inbred mice. Invest Ophthalmol Vis Sci 1984, 25(October (10)):1222-1225.
60. Stulting R.D., Kindle J.C., Nahmias A.J. Patterns of herpes simplex keratitis in inbred mice. Invest Ophthalmol Vis Sci 1985, 26(October (10)):1360-1367.
61. Kastrukoff L.F., Lau A.S., Puterman M.L. Genetics of natural resistance to herpes simplex virus type 1 latent infection of the peripheral nervous system in mice. J Gen Virol 1986, 67(April (Pt 4)):613-621.
62. Lopez C. Genetics of natural resistance to herpesvirus infections in mice. Nature 1975, 258(November (5531)):152-153.
63. McLean C.S., Erturk M., Jennings R., Challanain D.N., Minson A.C., Duncan I., et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994, 170(November (5)):1100-1109.
64. McLean G.W., Abbotts A.P., Parry M.E., Marsden H.S., Stow N.D. The herpes simplex virus type 1 origin-binding protein interacts specifically with the viral UL8 protein. J Gen Virol 1994, 75(October (Pt 10)):2699-2706.
65. Lecuru F., Taurelle R., Bernard J.P., Parrat S., Lafay-pillet M.C., Rozenberg F., et al. Varicella zoster virus infection during pregnancy: the limits of prenatal diagnosis. Eur J Obstet Gynecol Reprod Biol 1994, 56(July (1)):67-68.
66. Reddig P.J., Grinstead L.A., Monahan S.J., Johnson P.A., Parris D.S. The essential in vivo function of the herpes simplex virus UL42 protein correlates with its ability to stimulate the viral DNA polymerase in vitro. Virology 1994, 200(May (2)):447-456.
67. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994, 70(March (3)):369-380.
68. Stevens D.A., Merigan T.C. Approaches to the control of viral infections in man. Ration Drug Ther 1971, 5(September (9)):1-5.
69. Hoshino Y., Qin J., Follmann D., Cohen J.I., Straus S.E. The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia. Virology 2008, 372(March (1)):56-63.
70. + T cells. J Virol 2007, 81(August (15)):8157-8164.
71. Thompson R.L., Sawtell N.M. The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J Virol 1997, 71(July (7)):5432-5440.
72. Sawtell N.M. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J Virol 1997, 71(July (7)):5423-5431.
73. Dudek T.E., Torres-Lopez E., Crumpacker C., Knipe D.M. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011, 203(May (10)):1434-1441.
74. Dudek T., Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006, 344(January (1)):230-239.
75. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998, 392(March (6674)):394-397.
76. Lafferty W.E., Downey L., Celum C., Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000, 181(April (4)):1454-1457.
77. Straus S.E., Wald A., Kost R.G., McKenzie R., Langenberg A.G., Hohman P., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176(November (5)):1129-1134.
78. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997, 99(March (5)):1092-1097.
79. Wald A., Koutsky L., Ashley R.L., Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997, 24(March (3)):149-155.
80. Wald A., Schacker T., Corey L. HSV-2 and HIV: consequences of an endemic opportunistic infection. STEP Perspect 1997, 9(Winter (3)):2-4.
81. Hill J.M., Dudley J.B., Shimomura Y., Kaufman H.E. Quantitation and kinetics of induced HSV-1 ocular shedding. Curr Eye Res 1986, 5(March (3)):241-246.
82. Hill T.J., Yirrell D.L., Blyth W.A. Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse. J Gen Virol 1986, 67(February (Pt 2)):309-320.
83. Laibson P.R., Kibrick S. Recurrence of herpes simplex virus in rabbit eyes: results of a three-year study. Invest Ophthalmol 1969, 8(June (3)):346-350.
84. Chodosh J., Kennedy R.C. The conjunctival lymphoid follicle in mucosal immunology. DNA Cell Biol 2002, 21(May-June (5-6)):421-433.
85. Romanowski E.G, Araullo-Cruz T., Gordon Y.J. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 1997, 38(January (1)):253-257.
86. Romanowski E.G., Gordon Y.J., Araullo-Cruz T., Yates K.A., Kinchington P.R. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Invest Ophthalmol Vis Sci 2001, 42(July (8)):1812-1815.
87. Trousdale M.D., Dunkel E.C., Nesburn A.B. Effect of acyclovir on acute and latent herpes simplex virus infections in the rabbit. Invest Ophthalmol Vis Sci 1980, 19(November (11)):1336-1341.
88. Nesburn A.B., Common viral eye diseases, latent infections. Ophthalmology 1980, 87(December (12)):1202-1207.
89. Metcalf M.F., McNeill J.I., Kaufman H.E. Experimental disciform edema and necrotizing keratitis in the rabbit. Invest Ophthalmol 1976, 15(December (12)):979-985.
90. Knop N., Knop E. Ultrastructural anatomy of CALT follicles in the rabbit reveals characteristics of M-cells, germinal centres and high endothelial venules. J Anat 2005, 207(October (4)):409-426.
91. + T cells play disparate roles in the induction and the effector phases of murine experimental allergic conjunctivitis. Microbiol Immunol 2006, 50(9):719-728.
92. Fukushima A., Sumi T., Fukuda K., Kumagai N., Nishida T., Yagita H., et al. Interleukin 10 and transforming growth factor beta contribute to the development of experimentally induced allergic conjunctivitis in mice during the effector phase. Br J Ophthalmol 2006, 90(December (12)):1535-1541.
93. Gamache D.A., Dimitrijevich S.D., Weimer L.K., Lang L.S., Spellman J.M., Graff G., et al. Secretion of proinflammatory cytokines by human conjunctival epithelial cells. Ocul Immunol Inflamm 1997, 5(June (2)):117-128.
94. Wotherspoon A.C., Hardman-Lea S., Isaacson P.G. Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva. J Pathol 1994, 174(September (1)):33-37.
95. Knop E., Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. J Anat 2005, 206(March (3)):271-285.
96. Knop E., Knop N. Eye-associated lymphoid tissue (EALT) is continuously spread throughout the ocular surface from the lacrimal gland to the lacrimal drainage system. Ophthalmologe 2003, 100(November (11)):929-942.
97. Liu H., Meagher C.K., Moore C.P., Phillips T.E. M cells in the follicle-associated epithelium of the rabbit conjunctiva preferentially bind and translocate latex beads. Invest Ophthalmol Vis Sci 2005, 46(November (11)):4217-4223.
98. Bettahi I., Nesburn A.B., Yoon S., Zhang X., Mohebbi A., Sue V., et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci 2007, 48(October (10)):4643-4653.
99. + Tc1 responses and protect against ocular infection. J Virol 2005, 79(December (24)):15289-15301.
100. Bettahi I., Zhang X., Afifi R.E., BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol 2006, 19(Summer (2)):220-236.
101. Zhu X., Ramos T.V., Gras-Masse H., Kaplan B.E., BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 2004, 34(November (11)):3102-3114.
102. Nesburn A.B., Ramos T.V., Zhu X., Asgarzadeh H., Nguyen V., BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 2005, 23(January (7)):873-883.
103. Laycock K.A., Lee S.F., Brady R.H., Pepose J.S. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci 1991, 32(September (10)):2741-2746.
104. Sawtell N.M., Thompson R.L. Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol 1992, 66(April (4)):2157-2169.
105. Sawtell N.M., Thompson R.L. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol 1992, 66(April (4)):2150-2156.
106. + T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae 2011, 2(1):5.
107. Bonneau R.H., Zimmerman K.M., Ikeda S.C., Jones B.C. Differential effects of stress-induced adrenal function on components of the herpes simplex virus-specific memory cytotoxic T-lymphocyte response. J Neuroimmunol 1998, 82(March (2)):191-199.
108. + T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells. J Immunol 2011, 186(January (1)):183-194.
109. Elftman M.D., Hunzeker J.T., Mellinger J.C., Bonneau R.H., Norbury C.C., Truckenmiller M.E. Stress-induced glucocorticoids at the earliest stages of herpes simplex virus-1 infection suppress subsequent antiviral immunity, implicating impaired dendritic cell function. J Immunol 2010, 184(February (4)):1867-1875.
110. Sheridan J.F., Feng N.G., Bonneau R.H., Allen C.M., Huneycutt B.S., Glaser R. Restraint stress differentially affects anti-viral cellular and humoral immune responses in mice. J Neuroimmunol 1991, 31(March (3)):245-255.
111. + T cell control of latent herpes simplex virus type 1 infections. J Immunol 2007, 179(July (1)):322-328.
112. + T cell epitope-based vaccines against ocular herpes. J Immunol 2010, 184(March (5)):2561-2571.
113. Hu J., Peng X., Schell T.D., Budgeon L.R., Cladel N.M., Christensen N.D. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol 2006, 177(December (11)):8037-8045.
114. Barsam C.A., Brick D.J., Jones C., Wechsler S.L., Perng G.C. A viral model for corneal scarring and neovascularization following ocular infection of rabbits with a herpes simplex virus type 1 (HSV-1) mutant. Cornea 2005, 24(May (4)):460-466.
115. Mott K.R., Osorio N., Jin L., Brick D.J., Naito J., Cooper J., et al. The bovine herpesvirus-1 LR ORF2 is critical for this gene's ability to restore the high wild-type reactivation phenotype to a herpes simplex virus-1 LAT null mutant. J Gen Virol 2003, 84(November (Pt 11)):2975-2985.
116. Perng G.C., Maguen B., Jin L., Mott K.R., Osorio N., Slanina S.M., et al. A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J Virol 2002, 76(3):1224-1235.
117. Scriba M., Tatzber F. Pathogenesis of herpes simplex virus infections in guinea pigs. Infect Immun 1981, 34(December (3)):655-661.
118. Armerding D., Mayer P., Scriba M., Hren A., Rossiter H. In-vivo modulation of macrophage functions by herpes simplex virus type 2 in resistant and sensitive inbred mouse strains. Immunobiology 1981, 160(2):217-227.
119. Scriba M. Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs. Med Microbiol Immunol 1981, 169(2):91-96.
120. Bourne N., Stanberry L.R., Connelly B.L., Kurawadwala J., Straus S.E., Krause P.R. Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes. J Infect Dis 1994, 169(May (5)):1084-1087.
121. Krause P.R., Stanberry L.R., Bourne N., Connelly B., Kurawadwala J.F., Patel A., et al. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med 1995, 181(January (1)):297-306.
122. Bernstein D.I. Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 2001, 8(March (1)):8-11.
123. Stanberry L.R. The concept of immune-based therapies in chronic viral infections. J Acquir Immune Defic Syndr 1994, 7(Suppl 1):S1-S5.
124. Stanberry L.R. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev Infect Dis 1991, 13(November-December (Suppl 11)):S920-S923.
125. Boursnell M.E., Entwisle C., Blakeley D., Roberts C., Duncan I.A., Chisholm S.E., et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997, 175(January (1)):16-25.
126. Scriba M. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous herpes simplex virus: implications for a herpes virus vaccine. Med Microbiol Immunol (Berl) 1978, 166(November (1-4)):63-69.
127. Bourne N., Pyles R.B., Bernstein D.I., Stanberry L.R. Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol 2002, 83(November (Pt 11)):2797-2801.
128. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003, 187(February (4)):542-549.
129. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987, 155(May (5)):914-920.
130. Yim K.C., Carroll C.J., Tuyama A., Cheshenko N., Carlucci M.J., Porter D.D., et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 2005, 79(December (23)):14632-14639.
131. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005, 79(January (1)):410-418.
132. Richards C.M., Case R., Hirst T.R., Hill T.J., Williams N.A. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J Virol 2003, 77(June (12)):6692-6699.
133. Ghiasi H., Kaiwar R., Nesburn A.B., Slanina S., Wechsler S.L. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J Virol 1994, 68(April (4)):2118-2126.
134. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St-Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40(May (9)):1271-1281.
135. Dalai S.K., Pesnicak L., Miller G.F., Straus S.E. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol 2002, 8(February (1)):35-44.
136. Nesburn A.B., Ghiasi H., Wechsler S.L. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest Ophthalmol Vis Sci 1990, 31(August (8)):1497-1502.
137. Bravo F.J., Bourne N., Harrison C.J., Mani C., Stanberry L.R., Myers M.G., et al. Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. J Infect Dis 1996, 173(January (1)):1-6.
138. Willey D.E., Smith M.D., Nesburn A.B., Trousdale M.D. Sequential analysis of antibody responses in serum, aqueous humor and tear film during latent and induced recurrent HSV infections. Curr Eye Res 1985, 4(December (12)):1235-1240.
139. Yoshikawa T., Hill J.M., Stanberry L.R., Bourne N., Kurawadwala J.F., Krause P.R. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med 1996, 184(August (2)):659-664.
140. Bravo F.J., Myers M.G., Stanberry L.R. Neonatal herpes simplex virus infection: pathogenesis and treatment in the guinea pig. J Infect Dis 1994, 169(May (5)):947-955.
141. Knickelbein J.E., Hendricks R.L., Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol 2009, 54(March-April (2)):226-234.
142. Smith G.L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 1983, 302(April (5908)):490-495.
143. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(January (1)):62-73.
144. Nesburn A.B., Slanina S., Burke R.L., Ghiasi H., Bahri S., Wechsler S.L. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998, 72(October (10)):7715-7721.
145. Nesburn A.B., Burke R.L., Ghiasi H., Slanina S.M., Wechsler S.L. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 1998, 252(December (1)):200-209.
146. Nesburn A.B., Burke R.L., Ghiasi H., Slanina S.M., Wechsler S.L. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci 1998, 39(June (7)):1163-1170.
147. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vacc 2010, 9(September (9)):1055-1069.
148. Brandsma J.L., Shlyankevich M., Zhang L., Slade M.D., Goodwin E.C., Peh W., et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol 2004, 78(January (1)):116-123.
149. Barouch D.H. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010, 5(September (5)):386-390.
150. Patterson S., Papagatsias T., Benlahrech A. Use of adenovirus in vaccines for HIV. Handb Exp Pharmacol 2009, (188):275-293.
151. Walsh M.P., Chintakuntlawar A., Robinson C.M., Madisch I., Harrach B., Hudson N.R., et al. Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. PLoS ONE 2009, 4(6):e5635.
152. Smith J.G., Wiethoff C.M., Stewart P.L., Nemerow G.R. Adenovirus. Curr Top Microbiol Immunol 2010, 343:195-224.
153. Hanna L., Jawetz E., Mitsui Y., Thygeson P., Kimura S.J., Nicholas C. Continuing studies on the association of adenovirus type 8 with epidemic keratoconjunctivitis. Am J Ophthalmol 1957, 44(October (4, Part 2)):66-74.
154. Butt A.L., Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea 2006, 25(February (2)):199-202.
155. Ishiko H., Shimada Y., Konno T., Hayashi A., Ohguchi T., Tagawa Y., et al. Novel human adenovirus causing nosocomial epidemic keratoconjunctivitis. J Clin Microbiol 2008, 46(June (6)):2002-2008.
156. Aoki K., Ishiko H., Konno T., Shimada Y., Hayashi A., Kaneko H., et al. Epidemic keratoconjunctivitis due to the novel hexon-chimeric-intermediate 22,37/H8 human adenovirus. J Clin Microbiol 2008, 46(October (10)):3259-3269.
157. Chintakuntlawar A.V., Chodosh J. Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis. Ocul Immunol Inflamm 2010, 18(October (5)):341-345.
158. Ishiko H., Aoki K. Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan. J Clin Microbiol 2009, 47(August (8)):2678-2679.
159. Olofsson S., Kumlin U., Dimock K., Arnberg N. Avian influenza and sialic acid receptors: more than meets the eye?. Lancet Infect Dis 2005, 5(March (3)):184-188.
160. Trousdale M.D., Nobrega R., Wood R.L., Stevenson D., dos Santos P.M., Klein D., et al. Studies of adenovirus-induced eye disease in the rabbit model. Invest Ophthalmol Vis Sci 1995, 36(December (13)):2740-2748.
161. Iacobelli-Martinez M., Nemerow G.R. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J Virol 2007, 81(February (3)):1305-1312.
162. Wu E., Trauger S.A., Pache L., Mullen T.M., von Seggern D.J., Siuzdak G., et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J Virol 2004, 78(April (8)):3897-3905.
163. Trauger S.A., Wu E., Bark S.J., Nemerow G.R., Siuzdak G. The identification of an adenovirus receptor by using affinity capture and mass spectrometry. Chembiochem 2004, 5(August (8)):1095-1099.
164. Gordon Y.J., Araullo-Cruz T., Romanowski E., Myers B., Santora D., Lin M., et al. Replication of ocular isolates of human adenovirus is serotype-dependent in rabbit corneal organ culture. Curr Eye Res 1991, 10(March (3)):267-271.
165. Trousdale M.D., Nobrega R., Stevenson D., Nakamura T., dos Santos P.M., Labree L., et al. Role of adenovirus type 5 early region 3 in the pathogenesis of ocular disease and cell culture infection. Cornea 1995, 14(May (3)):280-289.
166. Sakurai F. Development of a replication-incompetent adenovirus vector derived from subgroup B adenovirus serotype 35. Yakugaku Zasshi 2008, 128(December (12)):1751-1761.
167. Barouch D.H., Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005, 16(February (2)):149-156.
168. Song K., Bolton D.L., Wei C.J., Wilson R.L., Camp J.V., Bao S., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci USA 2010, 107(December (51)):22213-22218.
169. Ahi Y.S., Bangari D.S., Mittal S.K. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011, 4(Aug (1)):307-320.
170. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415(January (6869)):331-335.
171. Dhaliwal D.K., Barnhorst D.A., Romanowski E., Rehkopf P.G., Gordon Y.J. Efficient reactivation of latent herpes simplex virus type 1 infection by excimer laser keratectomy in the experimental rabbit ocular model. Am J Ophthalmol 1998, 125(April (4)):488-492.
172. Romanowski E.G., Araullo-Cruz T., Gordon Y.J. Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 1998, 39(March (3)):532-536.
173. Borras T., Gabelt B.T., Klintworth G.K., Peterson J.C., Kaufman P.L. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001, 3(September-October (5)):437-449.
174. Yu M.J., Shen W.Y., Lai M.C., Constable I.J., Papadimitriou J.M., Rakoczy P.E. The role of vascular endothelial growth factor (VEGF) in abnormal vascular changes in the adult rat eye. Growth Factors 2000, 17(4):301-312.
175. Hamilton M.M., Brough D.E., McVey D., Bruder J.T., King C.R., Wei L.L. Repeated administration of adenovector in the eye results in efficient gene delivery. Invest Ophthalmol Vis Sci 2006, 47(January (1)):299-305.
176. Lemckert A.A., Grimbergen J., Smits S., Hartkoorn E., Holterman L., Berkhout B., et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006, 87(October (Pt 10)):2891-2899.
177. Havenga M., Vogels R., Zuijdgeest D., Radosevic K., Mueller S., Sieuwerts M., et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 2006, 87(August (Pt 8)):2135-2143.
178. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010, 84(April (7)):3270-3279.
179. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(January (7225)):87-91.
180. Barouch D.H., Liu J., Lynch D.M., O'Brien K.L., La Porte A., Simmons N.L., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009, 83(September (18)):9584-9590.
181. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16(March (3)):319-323.
182. Hamilton M.M., Byrnes G.A., Gall J.G., Brough D.E., King C.R., Wei L.L. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 2008, 14:2535-2546.